

New York State Oncology - Molecular Detection Proficiency Test - June 2007 (2007-2)
Summary of results

| Sample | NYS#L/L 1 (6-07) | | | | | | | | | | | | Overall dx: T cell clone with TCRG and TCRB rearrangement | | | | | | | | | | | | |
|---------------------------|------------------|---|-----|------|-----|---|-----|------|---------------------------|---|-----|------|---|---|-----|------|-------------|----|-------|-------------------------|--|--------------------------|-----------------------------|----------------------|--|
| | SB | | | | PCR | | | | Reverse Transcription-PCR | | | | FISH | | | | All methods | | | Method used | RT-PCR (qualitative) | RT-PCR (quantitative) | FISH | | |
| | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | Cons | SB | PCR | | | | |
| Ig H | 4 | 2 | R | | 23 | | G | | | | | I | | 2 | | G | 4 | 27 | R/G/G | Dako (4), home brew (2) | IVS (5), Biomed (6), home brew (13) | | | Vysis (1), other (1) | |
| Ig kappa | | 3 | G | | 6 | | G | | | | | I | | | | I | 0 | 9 | G | Dako (1), home brew (2) | IVS (1), Biomed (3), home brew (3) | | | | |
| Ig lambda | | 1 | I | | | | I | | | | | I | | | | I | 0 | 1 | I | home brew (1) | | | | | |
| TcR beta | 3 | 4 | I | | 7 | | R | | | | | I | | | | I | 10 | 4 | I/R | Dako (4), home brew (3) | Biomed (5), home brew (2) | | | | |
| TcR gamma | | | I | | 23 | | R | | | | | I | | | | I | 23 | 0 | R | | IVS (2), Biomed (3), home brew (18) | | | | |
| TcR delta | | 1 | I | | 1 | | I | | | | | I | | | | I | 0 | 2 | G | home brew (1) | home brew (1) | | | | |
| Bcl2 t(14;18) MBR | 1 | | I | | 14 | | G | | | | | I | | | | I | 0 | 15 | G | home brew (1) | Biomed (2), homebrew(11), IVS (1) | | | | |
| mcr | | | I | | 11 | | G | | | | | I | | | | I | 0 | 11 | G | | biomed (2), home brew (8), IVS (1) | | | | |
| MBR/mcr | | | I | | | | I | | | | | I | | 3 | | G | 0 | 3 | G | | | | | Vysis (3) | |
| MBR 3' | | | I | | 2 | | G | | | | | I | | | | I | 0 | 2 | G | | Biomed (2) | | | | |
| Bcl1 t(11;14) | 1 | | I | | 5 | | G | | | | | I | | 1 | | I | 0 | 7 | G | home brew (1) | home brew (3), other (2) | | | other (1) | |
| Bcr/abl t(9;22) p210 | | | I | | 3 | | G | 16 | | | | G | | | | I | 0 | 19 | G | | home brew (3) | home brew (5) | home brew (10), Ipsogen (1) | | |
| p190 | | | I | | 1 | | I | 14 | | | | G | | | | I | 0 | 15 | G | | home brew (1) | home brew (5) | home brew (8), Ipsogen (1) | | |
| p210/190 | | | I | | | | I | 6 | | | | G | 2 | | | G | 0 | 8 | G | | | home brew (3), Roche (3) | | Vysis (2) | |
| Abl kinase mutation | | | I | | | | I | 1 | | | | I | | | | I | 0 | 1 | I | | | n/a | | | |
| PML/RARa Long | | | I | | 1 | | I | 12 | | | | G | | | | I | 0 | 13 | G | | home brew (1) | home brew (6) | home brew (6) | | |
| Short | | | I | | 1 | | I | 10 | | | | G | | | | I | 0 | 11 | G | | | home brew (4) | home brew (6) | | |
| Variable | | | I | | 1 | | I | 3 | | | | G | | | | I | 0 | 4 | G | | | home brew (2) | home brew (1) | | |
| Long/Short/Variable | | | I | | | | I | | | | | I | 2 | | | G | 0 | 2 | G | | | | | Vysis (2) | |
| c-myc t(8;14) | | | I | | | | I | | | | | I | 2 | | | G | 0 | 2 | G | | | | | Vysis (2) | |
| AML1/ETO t(8;21) | | | I | | | | I | 7 | | | | G | 2 | | | G | 0 | 9 | G | | | home brew (5) | home brew (2) | Vysis (2) | |
| NPM/ALK t(2;5) | | | I | | | | I | 1 | | | | I | 2 | | | G | 0 | 3 | G | | | home brew (1) | | Vysis (2) | |
| TEL/AML1 t(12;21) | | | I | | | | I | 2 | | | | G | 1 | | | I | 0 | 3 | G | | | home brew (2) | | Vysis (1) | |
| EBV | | | I | | 3 | | G | | | | | I | | | | I | 0 | 3 | G | | home brew (2), Roche (1) | | | | |
| KSHV/HHV8 | | | I | | 4 | | G | | | | | I | | | | I | 0 | 4 | G | | home brew (4) | | | | |
| HTLV1 | | | I | | 3 | | G | | | | | I | | | | I | 0 | 3 | G | | home brew (3) | | | | |
| CBFB INV(16) | | | I | | | | I | 4 | | | | G | 2 | | | G | 0 | 6 | G | | | home brew (3) | home brew (1) | Other (2) | |
| E2A-PBX t(1;19) | | | I | | | | I | 1 | | | | I | | | | I | 0 | 1 | I | | | home brew (1) | | | |
| MLL (11q23) | | | I | | | | I | 2 | | | | G | 2 | | | G | 0 | 4 | G | | | home brew (2) | | Vysis (1), other (1) | |
| JAK2 (V617F) | | | I | | 18 | | G | 3 | | | | G | | | | I | 0 | 21 | G | | hb (14), IVS (1), other (2), Ipsogen (1) | home brew (1) | home brew (2) | | |
| FLT3 ITD | | | I | | 10 | | G | | | | | I | | | | I | 0 | 10 | G | | | home brew (10) | | | |
| FLT3 D835 | | | I | | 9 | | G | | | | | I | | | | I | 0 | 9 | G | | | home brew (9) | | | |
| P53 | | | I | | 1 | | I | | | | | I | 1 | | | I | 0 | 2 | G | | | home brew (1) | | Vysis (1) | |
| IgV _H mutation | | | I | | 1 | | I | 1 | | | | I | | | | I | 0 | 2 | G | | | home brew (1) | home brew (1) | | |
| c-kit | | | I | | 3 | | G | | | | | I | | | | I | 0 | 3 | G | | | home brew (3) | | | |
| BCL-6 | | | I | | | | I | | | | | I | 2 | | | G | 0 | 2 | G | | | | | other (1), Vysis (1) | |
| Other: CLL/MDS | | | I | | | | I | | | | | I | 1 | | | I | 0 | 1 | I | | | | | Vysis (1) | |

New York State Oncology - Molecular Detection Proficiency Test - June 2007 (2007-2)
Summary of results

| Sample | NYS#L/L 2 (6-07) | | | | Overall dx: B-cell clone with IgH & IgK rearrangement, c-myc transloc, P53 & IgVH mutation | | | | | | | | | | | | | | | | | | | | |
|---------------------------|------------------|---|-----|------|--|---|-----|------|---------------------------|---|-----|------|------|---|-----|------|-------------|----|------|-------------------------|---|--------------------------|-----------------------------|----------------------|----------------------|
| | SB | | | | PCR | | | | Reverse Transcription-PCR | | | | FISH | | | | All methods | | | Method used | | RT-PCR (qualitative) | RT-PCR (quantitative) | FISH | |
| | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | Cons | SB | PCR | | | | |
| Ig H | 6 | | | R | 24 | | | R | | | | I | 2 | | | R | 32 | 0 | R | Dako (4), home brew (2) | IVS (5), Biomed (6), home brew (14) | | | | Vysis (1) |
| Ig kappa | 3 | | | R | 6 | | | R | | | | I | | | | I | 9 | 0 | R | Dako (1), home brew (2) | IVS (1), Biomed (3), home brew (2) | | | | |
| Ig lambda | | 1 | | I | 1 | | | I | | | | I | | | | I | 0 | 2 | G | home brew (1) | home brew (1) | | | | |
| TcR beta | | 7 | | G | 7 | | | G | | | | I | | | | I | 0 | 14 | G | Dako (4), home brew (3) | Biomed (5) home brew (2) | | | | |
| TcR gamma | | | | I | 22 | | | G | | | | I | | | | I | 0 | 22 | G | | IVS (2) Biomed (3) home brew (17) | | | | |
| TcR delta | | 1 | | I | 1 | | | I | | | | I | | | | I | 0 | 2 | G | home brew (1) | home brew (1) | | | | |
| Bcl2 t(14;18) MBR | | 1 | | I | 13 | | | G | | | | I | | | | I | 0 | 14 | G | home brew (1) | Biomed (2) homebrew(10), IVS (1) | | | | |
| mcr | | | | I | 11 | | | G | | | | I | | | | I | 0 | 11 | G | | Biomed (2) homebrew(8), IVS (1) | | | | |
| MBR/mcr | | | | I | | | | I | | | | I | 3 | | | G | 0 | 3 | G | | | | | | Vysis (3) |
| MBR 3' | | | | I | 2 | | | G | | | | I | | | | I | 0 | 2 | G | | Biomed (2) | | | | |
| Bcl1 t(11;14) | | 1 | | I | 7 | | | G | | | | I | 3 | | | G | 0 | 11 | G | home brew (1) | homebrew (6), other (1) | | | | Vysis (2), other (1) |
| Bcr/abl t(9;22) p210 | | | | I | 4 | | | G | 16 | | | G | | | | I | 0 | 20 | G | | home brew (2) | home brew (5) | home brew (10), Ipsogen (1) | | |
| p190 | | | | I | 1 | | | I | 14 | | | G | | | | I | 0 | 15 | G | | home brew (1) | home brew (5) | home brew (8), Ipsogen (1) | | |
| p210/190 | | | | I | | | | I | 6 | | | G | 2 | | | G | 0 | 8 | G | | | Roche (2), home brew (1) | home brew (2), Roche (1) | Vysis (2) | |
| Abl kinase mutation | | | | I | | | | I | 1 | | | I | | | | I | 0 | 1 | I | | | n/a | | | |
| PML/RARa Long | | | | I | 1 | | | I | 12 | | | G | | | | I | 0 | 13 | G | | home brew (1) | home brew (6) | home brew (6) | | |
| Short | | | | I | 1 | | | I | 10 | | | G | | | | I | 0 | 11 | G | | | home brew (4) | home brew (6) | | |
| Variable | | | | I | 1 | | | I | 3 | | | G | | | | I | 0 | 4 | G | | | home brew (2) | home brew (1) | | |
| Long/Short/Variable | | | | I | | | | I | | | | I | 2 | | | G | 0 | 2 | G | | | | | | Vysis (2) |
| c-myc t(8;14) | | | | I | | | | I | | | | I | 4 | | | R | 4 | 0 | R | | | | | | Vysis (4) |
| AML1/ETO t(8;21) | | | | I | | | | I | 7 | | | G | 2 | | | G | 0 | 9 | G | | | home brew (5) | home brew (2) | Vysis (2) | |
| NPM/ALK t(2;5) | | | | I | | | | I | 1 | | | I | 2 | | | G | 0 | 3 | G | | | home brew (1) | | Vysis (2) | |
| TEL/AML1 t(12;21) | | | | I | | | | I | 2 | | | G | 1 | | | I | 0 | 3 | G | | | home brew (2) | | Vysis (1) | |
| EBV | | | | I | 3 | | | G | | | | I | | | | I | 0 | 3 | G | | home brew (2) Roche (1) | | | | |
| KSHV/HHV8 | | | | I | 4 | | | G | | | | I | | | | I | 0 | 4 | G | | home brew (4) | | | | |
| HTLV1 | | | | I | 3 | | | G | | | | I | | | | I | 0 | 3 | G | | home brew (3) | | | | |
| CBFB INV(16) | | | | I | | | | I | 4 | | | G | 2 | | | G | 0 | 6 | G | | | home brew (3) | home brew (1) | other (2) | |
| E2A-PBX t(1;19) | | | | I | | | | I | 1 | | | I | | | | I | 0 | 1 | I | | home brew (1) | | | | |
| MLL (11q23) | | | | I | | | | I | 2 | | | G | 2 | | | G | 0 | 4 | G | | | home brew (2) | | other (1), Vysis (1) | |
| JAK2 (V617F) | | | | I | 18 | | | G | 3 | | | G | | | | I | 0 | 21 | G | | hb (14), IVS(1), Ipsogen (1), other (2) | home brew (2) | home brew (1) | | |
| FLT3 ITD | | | | I | 10 | | | G | | | | I | | | | I | 0 | 10 | G | | home brew (10) | | | | |
| FLT3 D835 | | | | I | 9 | | | G | | | | I | | | | I | 0 | 9 | G | | home brew (9) | | | | |
| P53 | | | | I | 1 | | | I | | | | I | 1 | | | I | 2 | 0 | R | | home brew (1) | | | Vysis (1) | |
| IgV _H mutation | | | | I | 2 | | | R | 1 | | | I | | | | I | 3 | 0 | R | | home brew (2) | home brew (1) | | | |
| c-kit | | | | I | 3 | | | G | | | | I | | | | I | 0 | 3 | G | | home brew (3) | | | | |
| BCL-6 | | | | I | | | | I | | | | I | 3 | | | G | 0 | 3 | G | | | | | Vysis (2), other (1) | |
| Other: CLL/MDS | | | | I | | | | I | | | | I | 1 | | | I | 1 | 0 | I | | | | | Vysis (1) | |

New York State Oncology - Molecular Detection Proficiency Test - June 2007 (2007-2)
Summary of results

| Sample | NYS#L/L 3 (6-07) | | | | | | | | | | | | | | | | Overall dx: AML with MLL translocation | | | | | | | | | | | |
|---------------------------|------------------|---|-----|------|----|----|-----|------|-----|---|-----|------|---------------------------|---|-----|------|--|----|-----|------|-------------------------|---|--------------------------|-----------------------------|----------------------|----------------------|-----------------------|------|
| | Assay | | | | SB | | | | PCR | | | | Reverse Transcription-PCR | | | | FISH | | | | All methods | | | Method used | | RT-PCR (qualitative) | RT-PCR (quantitative) | FISH |
| | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | Cons | SB | PCR | | | |
| Ig H | | 6 | | G | | 23 | | G | | | | I | | 2 | | G | 0 | 31 | | G | Dako (4), home brew (2) | IVS (5), Biomed (6), home brew (12) | | | | | Vysis (2), other (1) | |
| Ig kappa | | 3 | | G | | 6 | | G | | | | I | | | | I | 0 | 9 | | G | Dako (1), home brew (2) | IVS (1), Biomed (3), home brew (2) | | | | | | |
| Ig lambda | | 1 | | I | | 1 | | I | | | | I | | | | I | 0 | 2 | | G | home brew (1) | home brew (1) | | | | | | |
| TcR beta | | 7 | | G | | 7 | | G | | | | I | | | | I | 0 | 14 | | G | Dako (4), home brew (3) | Biomed (5) home brew (2) | | | | | | |
| TcR gamma | | | | I | 1 | 20 | 1 | G | | | | I | | | | I | 1 | 20 | | G | | IVS (2) Biomed (3) home brew (17) | | | | | | |
| TcR delta | | 1 | | I | | 1 | | I | | | | I | | | | I | 0 | 2 | | G | home brew (1) | home brew (1) | | | | | | |
| Bcl2 t(14;18) MBR | | 1 | | I | | 14 | | G | | | | I | | | | I | 0 | 15 | | G | home brew (1) | Biomed (2) homebrew(11), IVS (1) | | | | | | |
| mcr | | | | I | | 11 | | G | | | | I | | | | I | 0 | 11 | | G | | Biomed (2), IVS (1), home brew (8) | | | | | | |
| MBR/mcr | | | | I | | | | I | | | | I | 2 | | | G | 0 | 2 | | G | | | | | | | Vysis (2) | |
| MBR 3' | | | | I | | 2 | | G | | | | I | | | | I | 0 | 2 | | G | | Biomed (2) | | | | | | |
| Bcl1 t(11;14) | | 1 | | I | | 7 | | G | | | | I | 2 | | | G | 0 | 10 | | G | home brew (1) | homebrew (6), other (1) | | | | | Vysis (1), other (1) | |
| Bcr/abl t(9;22) p210 | | | | I | | 3 | | G | 16 | | | G | | | | I | 0 | 19 | | G | | homebrew (3), Ipsogen (1) | home brew (5) | home brew (10), Ipsogen (1) | | | | |
| p190 | | | | I | | 1 | | I | 14 | | | G | | | | I | 0 | 15 | | G | | home brew (1) | home brew (5) | home brew (8), Ipsogen (1) | | | | |
| p210/190 | | | | I | | | | I | 6 | | | G | 4 | | | G | 0 | 10 | | G | | | Roche (2), home brew (1) | Roche (1), home brew (2) | Vysis (4) | | | |
| Abl kinase mutation | | | | I | | | | I | 1 | | | I | | | | I | 0 | 1 | | I | | | n/a | | | | | |
| PML/RARa Long | | | | I | | 1 | | I | 12 | | | G | | | | I | 0 | 13 | | G | | home brew (1) | home brew (6) | home brew (6) | | | | |
| Short | | | | I | | 1 | | I | 10 | | | G | | | | I | 0 | 11 | | G | | home brew (1) | home brew (4) | home brew (6) | | | | |
| Variable | | | | I | | 1 | | I | 3 | | | G | | | | I | 0 | 4 | | G | | home brew (1) | home brew (2) | home brew (1) | | | | |
| Long/Short/Variable | | | | I | | | | I | | | | I | 4 | | | G | 0 | 4 | | G | | | | | | | Vysis (4) | |
| c-myc t(8;14) | | | | I | | | | I | | | | I | 2 | | | G | 0 | 2 | | G | | | | | | | Vysis (2) | |
| AML1/ETO t(8;21) | | | | I | | | | I | 7 | | | G | 3 | | | G | 0 | 10 | | G | | | home brew (5) | home brew (2) | Vysis (3) | | | |
| NPM/ALK t(2;5) | | | | I | | | | I | 1 | | | I | 2 | | | G | 0 | 3 | | G | | | home brew (1) | | Vysis (2) | | | |
| TEL/AML1 t(12;21) | | | | I | | | | I | 2 | | | G | 1 | | | I | 0 | 3 | | G | | | home brew (2) | | Vysis (1) | | | |
| EBV | | | | I | | 3 | | G | | | | I | | | | I | 0 | 3 | | G | | home brew (2) Roche (1) | | | | | | |
| KSHV/HHV8 | | | | I | | 4 | | G | | | | I | | | | I | 0 | 4 | | G | | home brew (4) | | | | | | |
| HTLV1 | | | | I | | 3 | | G | | | | I | | | | I | 0 | 3 | | G | | home brew (3) | | | | | | |
| CBFB INV(16) | | | | I | | | | I | 3 | | | G | 3 | | | G | 0 | 6 | | G | | | home brew (2) | home brew (1) | Vysis (2), other (1) | | | |
| E2A-PBX t(1;19) | | | | I | | | | I | 1 | | | I | | | | I | 0 | 1 | | I | | | home brew (1) | | | | | |
| MLL (11q23) | | | | I | | | | I | 2 | | | G | 3 | | | R | 3 | 2 | | G/R | | | home brew (2) | | Other (1), Vysis (2) | | | |
| JAK2 (V617F) | | | | I | | 18 | | G | 3 | | | G | | | | I | 0 | 21 | | G | | homebrew(14), Ipsogen (1), IVS (1), oth (2) | home brew (2) | home brew (1) | | | | |
| FLT3 ITD | | | | I | | 10 | | G | | | | I | | | | I | 0 | 10 | | G | | homebrew (10) | | | | | | |
| FLT3 D835 | | | | I | | 9 | | G | | | | I | | | | I | 0 | 9 | | G | | home brew (9) | | | | | | |
| P53 | | | | I | | 1 | | I | | | | I | 1 | | | I | 1 | 1 | | I | | home brew (1) | | | | | other (1) | |
| IgV _H mutation | | | | I | | 1 | | I | 1 | | | I | | | | I | 0 | 2 | | G | | home brew (1) | home brew (1) | | | | | |
| c-kit | | | | I | | 3 | | G | | | | I | | | | I | 0 | 3 | | G | | home brew (3) | | | | | | |
| BCL-6 | | | | I | | | | I | | | | I | 2 | | | G | 0 | 2 | | G | | | | | | | Vysis (1), other (1) | |
| Other: CLL/MDS | | | | I | | | | I | | | | I | 1 | | | I | 1 | 0 | | I | | | | | | | Vysis (1) | |